Evidence map›Paper›PMID 36792569›Full record

ArticleImmunity2023

X marks the shot against malaria.

Raphael A Reyes, Rolando Garza, Evelien M Bunnik

Abstract readComment
PubMed Publisher
In one paragraph

Article in Immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Raphael A ReyesDepartment of Microbiology, Immunology & Molecular Genetics, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Rolando GarzaDepartment of Microbiology, Immunology & Molecular Genetics, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Evelien M BunnikDepartment of Microbiology, Immunology & Molecular Genetics, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Electronic address: bunnik@uthscsa.edu.

Funding

Defining conserved epitopes on polymorphic malaria antigensR01AI153425 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BUNNIK, EVELIEN MARGARETHA · 2021 to 2025
$2.7M
Molecular and cellular properties of broad and protective immune responses to the Plasmodium falciparum variant surface antigen responsible for severe malariaF31AI169993 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI REYES, RAPHAEL ANTHONY · 2022 to 2023
$46k
NIAID NIH HHS F31 AI169993NIAID NIH HHS R01 AI153425
6 · The paper itself

Abstract

The development of a transmission-blocking vaccine (TBV) against malaria is hampered by poor understanding of functional antibody responses. In this issue of Immunity, Fabra-Garcia et al., Ivanochko et al., and Tang et al. isolate human monoclonal antibodies against the two most promising TBV candidates, Pfs48/45 and Pfs230, and map the epitopes responsible for potent transmission-reducing activity.

Indexed as

MalariaMalaria, FalciparumMalaria VaccinesAntibodies, ProtozoanAntigens, ProtozoanHumansPlasmodium falciparumProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesProtozoan Proteins

Identifiers

PMID36792569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.